ReviewAdvances in pharmacology (San Diego, Calif.)2010
The cardiovascular physiology and pharmacology of endothelin-1.
Review in Advances in pharmacology (San Diego, Calif.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 86 citations in OpenAlex.
- Menopause and vascular endothelial health: Is it all about the oestrogen?Experimental physiology · 2026Review
- The machinery of healthy vasoconstriction: an overview.Pflugers Archiv : European journal of physiology · 2025Review
- Can Endothelin-1 Help Address the Diagnostic and Prognostic Challenges in Multimorbid Acute Heart Failure Patients?Life (Basel, Switzerland) · 2025Article
- Short-term estradiol administration does not restore endothelin-B receptor-mediated vasodilation in postmenopausal women.American journal of physiology. Heart and circulatory physiology · 2025Article
- Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients.American journal of hypertension · 2024Article
- Preliminary evidence that blocking the uptake of placenta-derived preeclamptic extracellular vesicles protects the vascular endothelium and prevents vasoconstriction.Scientific reports · 2023Article
- Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?Diagnostics (Basel, Switzerland) · 2023Review
- Microvascular Function, Inflammatory Status, and Oxidative Stress in Post-Bariatric Patients with Weight Regain.Nutrients · 2023Article
- Endothelin-1 Induced Phosphorylation of Caveolin-1 and Smad2C in Human Vascular Smooth Muscle Cells: Role of NADPH Oxidases, c-Abl, and Caveolae Integrity in TGF-β Receptor Transactivation.International journal of molecular and cellular medicine · 2022Article
- Human Cytomegalovirus Reduces Endothelin-1 Expression in Both Endothelial and Vascular Smooth Muscle Cells.Microorganisms · 2021Article
- Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage.Therapeutic advances in neurological disorders · 2021Review
- Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer's Disease.Journal of personalized medicine · 2020Review
- Pro-remodeling peptides modulate collagen α1(I) promoter activity in rat cardiac myofibroblasts.Biochemical and biophysical research communications · 2019Article
- The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Review
- Targeting vascular (endothelial) dysfunction.British journal of pharmacology · 2017Review
- Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.Journal of clinical medicine · 2017Review
- Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.Life sciences · 2016Review
- Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System.Cardiovascular toxicology · 2016Review
- Lung Circulation.Comprehensive Physiology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
One year after the discovery in 1980 that the endothelium was obligatory for acetylcholine to relax isolated arteries, it was clearly shown that the endothelium could also promote contraction. In 1988, Dr Yanagisawa's group identified endothelin-1 (ET-1) as the first endothelium-derived contracting factor. The circulating levels of this short (21 amino acids) peptide were quickly determined in humans and it was reported that in most cardiovascular diseases, circulating levels of ET-1 were increased and ET-1 was then recognized as a likely mediator of pathological vasoconstriction in human. The discovery of two receptor subtypes in 1990, ET(A) and ET(B), permitted optimization of bosentan, which entered clinical development in 1993, and was offered to patients with pulmonary arterial hypertension in 2001. In this report, we discuss the physiological and pathophysiological role of endothelium-derived ET-1, the pharmacology of its two receptors, focusing on the regulation of the vascular tone and as much as possible in humans. The coronary bed will be used as a running example, but references to the pulmonary, cerebral, and renal circulation will also be made. Many of the cardiovascular complications associated with aging and cardiovascular risk factors are initially attributable, at least in part, to endothelial dysfunction, particularly dysregulation of the vascular function associated with an imbalance in the close interdependence of NO and ET-1, in which the implication of the ET(B) receptor may be central.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.